NCT00005070View on ClinicalTrials.gov

Irofulven in Treating Patients With Stage IVB or Recurrent Cervical Cancer

PHASE2CompletedINTERVENTIONAL
Timeline

Start Date

January 31, 2000

Primary Completion Date

May 31, 2001

Study Completion Date

May 31, 2001

Conditions
Cervical Cancer
Interventions
DRUG

irofulven

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT00005070 - Irofulven in Treating Patients With Stage IVB or Recurrent Cervical Cancer | Biotech Hunter | Biotech Hunter